Clinical trial

Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally…

NCT00049283 · National Cancer Institute (NCI), NIH · Completed

Key facts

NCT number NCT00049283
Title Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer
Official title A Phase I Study of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, OSI-774, in Combination With Docetaxel and Radiation in Locally Advanced Squamous Cell Cancer of the Head and Neck
Lead sponsor National Cancer Institute (NCI), NIH
Status Completed
Phase Phase 1
Study type Interventional
Conditions Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Verrucous Carcinoma of the Larynx, Stage III Verrucous Carcinoma of the Oral Cavity, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx and 17 more
Intervention type Drug, Other, Procedure, Radiation
Interventions erlotinib hydrochloride, docetaxel, radiation therapy, therapeutic conventional surgery, laboratory biomarker analysis, pharmacological study
Enrollment 30
Start date Sep 1, 2002
Primary completion Feb 1, 2008
Completion Feb 1, 2008
First posted Jan 27, 2003
Last update posted Jun 6, 2014
Countries United States

At a glance

  • 1–9 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies